Paul M Galatsis from 375 Cherry St, Newton, MA 02465, age 66, Phone: 7347611953

Us Patents

Arylsulfonamide Ethers, And Methods Of Use Thereof
view source
US Patent:

6875765, Apr 5, 2005
Filed:

May 10, 2002
Appl. No.:

10/143675
Inventors:

James Knobelsdorf - Knoblesville IN, US
Sheryl Hays - Ann Arbor MI, US
Charles J. Stankovic - Saline MI, US
Kimberly S. Para - Ann Arbor MI, US
Michael K. Connolly - Ypsilanti MI, US
Paul Galatsis - Ann Arbor MI, US
William Harter - Chelsea MI, US
Aurash B. Shahripour - Ann Arbor MI, US
Mark Stephen Plummer - Dexter MI, US
Beth Lunney - San Diego CA, US
Bernd Janssen - Marlborough MA, US
Jay Bradford Fell - Longmont CO, US
Assignee:

Warner-Lambert Company - Morris Plains NJ
International Classification:

C07D295/14
C07D407/12
C07D487/04
A61K031/495
A61P019/02
US Classification:

5142382, 51425212, 514303, 514311, 514312, 514307, 514331, 514365, 514368, 514394, 514400, 514405, 514562, 544159, 544399, 546118, 546149, 546157, 546172, 546235, 548154, 548204, 5483087, 5483097, 5483385, 5483625, 562430
Abstract:

The novel arylsulfonamide ether compounds, pharmaceutical compositions and uses thereof as inhibitors of interleukin-1β converting enzyme and other cysteine proteases in the ICE family are described. In one embodiment, the compound is described by the generalized structure: and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof. In addition, methods of treating stroke, inflammatory diseases, septic shock, repurfusion injury, Alzheimer's disease, and shigellosis, using a compound of the invention or a pharmaceutical composition thereof, are described.

Hydroxamate Inhibitors Of Interleukin-1.Beta. Converting Enzyme
view source
US Patent:

59197900, Jul 6, 1999
Filed:

Oct 2, 1997
Appl. No.:

8/942605
Inventors:

Hamish John Allen - Shrewsbury MA
Kenneth Dale Brady - Worcester MA
Bradley William Caprathe - Livonia MI
Paul Galatsis - Ann Arbor MI
John Lodge Gilmore - Ann Arbor MI
Sheryl Jeanne Hays - Ann Arbor MI
Robert Vincent Talanian - Harvard MA
Nigel Walker - Dossenheim, DE
Joseph Scott Warmus - Ann Arbor MI
Assignee:

Warner-Lambert Company - Morris Plains NJ
BASF Aktiengesellsschaft - Ludwigshafen
International Classification:

A61K 31405
A61K 3144
C07C25908
C07C22932
C07D20934
C07D20946
C07D20948
C07D22120
US Classification:

514278
Abstract:

The present invention relates to compounds that are inhibitors of interleukin-1. beta. converting enzyme that have the Formula II ##STR1## This invention also relates to a method of treatment of stroke, inflammatory diseases, septic shock, reperfusion injury, Alzheimer's disease, shigellosis, and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-1. beta. converting enzyme.

Novel Imidazo[4,5-C]Quinoline Derivatives As Lrrk2 Inhibitors
view source
US Patent:

20210355117, Nov 18, 2021
Filed:

Mar 6, 2018
Appl. No.:

16/492558
Inventors:

- New York NY, US
Thomas Allen CHAPPIE - Carlisle MA, US
Jinshan Michael CHEN - Madison CT, US
Jotham Wadsworth COE - Niantic CT, US
Karen Jean COFFMAN - Pawcatuck CT, US
Paul GALATSIS - Newton MA, US
Michelle Renee GARNSEY - Providence RI, US
Christopher John HELAL - Mystic CT, US
Jaclyn Louise Henderson - Cambridge MA, US
Bethany Lyn KORMOS - Somerville MA, US
Ravi G. KURUMBAIL - East Lyme CT, US
Luis Angel MARTINEZ-ALSINA - Gales Ferry CT, US
Martin Youngjin PETTERSSON - Littleton MA, US
Matthew Richard REESE - Mystic CT, US
Colin Richard ROSE - Quaker Hill CT, US
Antonia Friederike STEPAN - Biberach an der Riss, DE
Patrick Robert VERHOEST - Newton MA, US
Travis T. WAGER - Brookline MA, US
Joseph Scott WARMUS - Ledyard CT, US
Yuan ZHANG - East Lyme CT, US
International Classification:

C07D 471/04
Abstract:

The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R, Rand Rare as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

Cyclic Substituted Imidazo[4,5-C]Quinoline Derivatives
view source
US Patent:

20200039977, Feb 6, 2020
Filed:

Mar 1, 2018
Appl. No.:

16/492554
Inventors:

- New York NY, US
Paul Galatsis - Newton MA, US
Michelle Renee Garnsey - Providence RI, US
Christopher John Helal - Mystic CT, US
Jaclyn Louise Henderson - Cambridge MA, US
Bethany Lyn Kormos - Somerville MA, US
Ravi G. Kurumbail - East Lyme CT, US
Luis Angel Martinez-Alsina - Gales Ferry CT, US
Martin Youngjin Pettersson - Littleton MA, US
Antonia Friederike Stepan - Biberach An Der Riss, DE
Travis T. Wager - Brookline MA, US
International Classification:

C07D 471/04
C07D 471/14
Abstract:

The present invention provides novel cyclic substituted imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.